FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 8933 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| Electroacupuncture vs Sham Electroacupuncture in the Treatment of Postoperative Ileus After Laparoscopic Surgery for Colorectal Cancer: A Multicenter, Randomized Clinical Trial. PMID 36322060 · JAMA Surg · 2023-Jan-01 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| Patient-reported outcomes with cemiplimab monotherapy for first-line treatment of advanced non-small cell lung cancer with PD-L1 of ≥50%: The EMPOWER-Lung 1 study. PMID 36308296 · Cancer · 2023-Jan-01 The record describes a quality-of-life analysis from the EMPOWER-Lung 1 trial, which is a randomized Phase III trial (implied by the trial name and ClinicalTrials.gov ID NCT03088540, but not explicitly stated in the provided metadata). However, the primary endpoint of this specific report is patient-reported outcomes (quality of life and symptom burden), not a traditional time-to-event efficacy endpoint like OS, PFS, or DFS. Therefore, it does not meet the criteria for inclusion as a Kaplan-Meier efficacy endpoint report. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Phase 1 Randomized Trial of Stereotactic Body Radiation Therapy Followed by Nivolumab plus Ipilimumab or Nivolumab Alone in Advanced/Unresectable Hepatocellular Carcinoma. PMID 36108891 · Int J Radiat Oncol Biol Phys · 2023-Jan-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Quality-of-Life Outcomes and Toxicity Profile Among Patients With Localized Prostate Cancer After Radical Prostatectomy Treated With Stereotactic Body Radiation: The SCIMITAR Multicenter Phase 2 Trial. PMID 36007724 · Int J Radiat Oncol Biol Phys · 2023-Jan-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Pexidartinib Provides Modest Pain Relief in Patients With Tenosynovial Giant Cell Tumor: Results From ENLIVEN. PMID 36001000 · Clin Orthop Relat Res · 2023-Jan-01 The study is a Phase III randomized drug trial in oncology, but the primary endpoint analyzed in this report is pain relief, a patient-reported outcome, not a time-to-event efficacy endpoint required for inclusion. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| The TARGIT-A Randomized Trial: TARGIT-IORT Versus Whole Breast Radiation Therapy: Long-Term Local Control and Survival. PMID 35998867 · Int J Radiat Oncol Biol Phys · 2023-Jan-01 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| A Randomized, Double-Blind, Biomarker-Selected, Phase II Clinical Trial of Maintenance Poly ADP-Ribose Polymerase Inhibition With Rucaparib Following Chemotherapy for Metastatic Urothelial Carcinoma. PMID 35960902 · J Clin Oncol · 2023-Jan-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Improved outcomes with "7+3" induction chemotherapy for acute myeloid leukemia over the past four decades: analysis of SWOG trial data. PMID 35833298 · Haematologica · 2023-Jan-01 The study is a human oncology randomized trial analyzing time-to-event outcomes for a drug intervention. However, the abstract does not explicitly state that the included SWOG trials (S8600, S9031, S9333, S0106, S1203) are Phase III or Phase II/III. The publication type is 'Randomized Controlled Trial' but does not specify phase. Therefore, the phase criterion cannot be definitively established from the provided metadata. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| A Randomized Controlled Clinical Trial of Transanal Irrigation Versus Conservative Treatment in Patients With Low Anterior Resection Syndrome After Rectal Cancer Surgery. PMID 35797618 · Ann Surg · 2023-Jan-01 The trial is a randomized, controlled study in rectal cancer patients, but it compares two non-drug interventions (transanal irrigation vs. conservative treatment) and its primary endpoint is a functional/symptom score (LARS score) at 12 months, not a time-to-event efficacy endpoint such as overall survival or progression-free survival. Therefore, it does not meet the required drug intervention or time-to-event endpoint criteria. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Durvalumab Plus Olaparib in Previously Untreated, Platinum-Ineligible Patients With Metastatic Urothelial Carcinoma: A Multicenter, Randomized, Phase II Trial (BAYOU). PMID 35737919 · J Clin Oncol · 2023-Jan-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| An Estimate of Local Failure in the TARGIT-A Trial of Pre-pathology Intraoperative Radiation Therapy for Early Breast Cancer. PMID 35065848 · Int J Radiat Oncol Biol Phys · 2023-Jan-01 The study is a secondary analysis of the TARGIT-A trial, estimating local failure from previously published survival curves. The intervention (intraoperative radiation therapy) is not a drug-containing regimen. Furthermore, the phase of the original trial is not explicitly confirmed as Phase III/IIIb or Phase II/III within the provided metadata. Therefore, it does not meet the eligibility criteria for inclusion in the oncology Kaplan-Meier digitization cohort. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| On the Choice of Longitudinal Models for the Analysis of Antitumor Efficacy in Mouse Clinical Trials of Patient-derived Xenograft Models. PMID 36968232 · Cancer Res Commun · 2023-Jan Study is a preclinical animal model analysis (mice) of tumor growth statistics, not a human clinical trial. No time-to-event efficacy endpoint (OS, PFS, etc.) is analyzed or reported. Does not meet the core requirement of being a human Phase III/IIIb or II/III randomized trial with a drug-containing intervention and a primary/key secondary time-to-event endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Identification of an endoplasmic reticulum stress-related gene signature to predict prognosis and potential drugs of uterine corpus endometrial cancer. PMID 36899615 · Math Biosci Eng · 2023-Jan The record is a bioinformatics/prognostic biomarker study using retrospective data from TCGA. It is not a report of a randomized clinical trial with a drug intervention. The 'Randomized Controlled Trial' publication type is likely a misclassification by PubMed or the database. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| LITESPARK-011: belzutifan plus lenvatinib vs cabozantinib in advanced renal cell carcinoma after anti-PD-1/PD-L1 therapy. PMID 36752726 · Future Oncol · 2023-Jan The record is a clinical trial protocol for a phase III randomized trial in oncology with a drug intervention, but it does not report results or explicitly identify a primary/key secondary time-to-event efficacy endpoint (e.g., OS, PFS) with Kaplan-Meier or HR data. As a protocol, it does not meet the requirement for an original formal-result report. |
H
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Recent Advances in Sentinel Node Navigation Surgery for Early Gastric Cancer. PMID 36750996 · J Gastric Cancer · 2023-Jan 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| [Dawn of Radical Segmentectomy for Small Sized Peripheral Non-small Cell Lung Cancer]. PMID 36731826 · Kyobu Geka · 2023-Jan 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| Homologous Recombination Repair Gene Mutations to Predict Olaparib Plus Bevacizumab Efficacy in the First-Line Ovarian Cancer PAOLA-1/ENGOT-ov25 Trial. PMID 36716415 · JCO Precis Oncol · 2023-Jan This is an exploratory biomarker analysis (subgroup) from the PAOLA-1 trial, not the primary report of the randomized trial's main efficacy endpoint. The trial phase is not explicitly confirmed as Phase III/IIIb or II/III in the provided metadata (it is known to be Phase III, but the instruction is to not infer missing phase). Therefore, it does not meet the 'original formal-result report' criterion. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| A multicenter, randomized, double-blind, placebo-controlled, phase 3 trial of olanzapine plus triple antiemetic regimen for the prevention of multiday highly emetogenic chemotherapy-induced nausea and vomiting (OFFER study). PMID 36712888 · EClinicalMedicine · 2023-Jan The trial is a randomized Phase III study in oncology with a drug intervention, but its primary efficacy endpoint is complete response rate (a categorical proportion), not a time-to-event endpoint such as OS, PFS, DFS, EFS, RFS, TTP, or a Kaplan-Meier/HR analysis. Therefore, it does not meet the cohort's requirement for a primary/key secondary time-to-event efficacy endpoint. |
H
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Magnesium Supplementation Affects the Expression of Sirtuin1, Tumor Protein P53 and Endothelial Nitric Oxide Synthase Genes in Patients with Atherosclerosis: A Double-Blind, Randomized, Placebo-Controlled Trial. PMID 36684501 · Indian J Clin Biochem · 2023-Jan The study is a randomized, placebo-controlled trial of magnesium supplementation in patients with atherosclerosis (a cardiovascular condition), not a human malignant neoplasm. It does not report a time-to-event efficacy endpoint such as OS, PFS, DFS, EFS, RFS, TTP, or survival analysis via Kaplan-Meier curves or hazard ratios. The outcomes are gene expression changes, which are not time-to-event efficacy endpoints. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| A nomogram for predicting overall survival in patients with type II endometrial carcinoma: a retrospective analysis and multicenter validation study. PMID 36647873 · Eur Rev Med Pharmacol Sci · 2023-Jan The record describes a retrospective nomogram validation study, not a randomized controlled trial of a drug intervention in a Phase III setting. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Impact of Anti-HER2 Therapy Alone and With Weekly Paclitaxel on the Ovarian Reserve of Young Women With HER2-Positive Breast Cancer. PMID 36634607 · J Natl Compr Canc Netw · 2023-Jan The record describes a biomarker analysis of AMH levels from the NeoALTTO trial, which is a randomized phase III study with drug interventions. However, the primary endpoint reported is the change in ovarian reserve (AMH levels), not a time-to-event efficacy endpoint like OS, PFS, DFS, EFS, RFS, TTP, or results presented via Kaplan-Meier/Hazard Ratio. Therefore, it does not meet the key inclusion criterion for a time-to-event efficacy endpoint. |
H
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| New prognostic model in patients with advanced urothelial carcinoma treated with second-line immune checkpoint inhibitors. PMID 36627145 · J Immunother Cancer · 2023-Jan The record is from a single-arm phase IIIb trial, not a randomized trial. While it is oncology, human, involves a drug intervention, and reports a time-to-event endpoint (OS), the lack of randomization makes it ineligible for this cohort. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Target Trial Emulation: A Design Tool for Cancer Clinical Trials. PMID 36608311 · JCO Clin Cancer Inform · 2023-Jan The record describes a methodological study applying target trial emulation to simulate a randomized trial of a non-drug intervention (radioembolization). It is not an original report of a Phase III randomized trial of a drug intervention with a time-to-event efficacy endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Historic Clinical Trial External Control Arm Provides Actionable GEN-1 Efficacy Estimate Before a Randomized Trial. PMID 36608308 · JCO Clin Cancer Inform · 2023-Jan 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Anti-SARS-CoV-2 antibody-containing plasma improves outcome in patients with hematologic or solid cancer and severe COVID-19: a randomized clinical trial. PMID 36581734 · Nat Cancer · 2023-Jan While the trial is randomized and includes a drug intervention (convalescent plasma) with time-to-event outcomes, the cancer cohort is a subgroup within a broader COVID-19 trial (not a dedicated oncology trial), the primary endpoint is an ordinal scale (not a standard time-to-event endpoint like OS or PFS), and the phase is not explicitly reported as Phase III/IIIb or Phase II/III. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Comparison of the effect of oral megestrol acetate with or without levonorgestrel-intrauterine system on fertility-preserving treatment in patients with early-stage endometrial cancer: a prospective, open-label, randomized controlled phase II trial (ClinicalTrials.gov NCT03241914). PMID 36562136 · J Gynecol Oncol · 2023-Jan 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial. PMID 36528035 · Lancet Oncol · 2023-Jan 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Developing a prediction model for all-cause mortality risk among patients with type 2 diabetes mellitus in Shanghai, China. PMID 36526273 · J Diabetes · 2023-Jan The record describes a non-oncology (diabetes) prediction model development study using an observational cohort. It is not a Phase II/III or Phase III/IIIb randomized trial of a drug intervention for a malignant neoplasm with a time-to-event efficacy endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Pembrolizumab versus cetuximab concurrent with radiotherapy in patients with locally advanced squamous cell carcinoma of head and neck unfit for cisplatin (GORTEC 2015-01 PembroRad): a multicenter, randomized, phase II trial. PMID 36522816 · Ann Oncol · 2023-Jan 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| REFINE (REduced Frequency ImmuNE checkpoint inhibition in cancers): A multi-arm phase II basket trial testing reduced intensity immunotherapy across different cancers. PMID 36519749 · Contemp Clin Trials · 2023-Jan 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Long-Term Health-Related Quality of Life in Patients with Plaque Psoriasis Treated with Certolizumab Pegol: Three-Year Results from Two Randomised Phase 3 Studies (CIMPASI-1 and CIMPASI-2). PMID 36509889 · Dermatol Ther (Heidelb) · 2023-Jan The study is a randomized Phase 3 trial of a drug (certolizumab pegol) with original results, but it is not in oncology (psoriasis) and the reported endpoints are quality-of-life outcomes, not time-to-event efficacy endpoints (e.g., OS, PFS, DFS, etc.) or Kaplan-Meier/HR analyses. |
H
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Prognostic value of baseline functional status measures and geriatric screening in vulnerable older patients with metastatic colorectal cancer receiving palliative chemotherapy - The randomized NORDIC9-study. PMID 36494261 · J Geriatr Oncol · 2023-Jan The study is a randomized, oncology, human trial with drug intervention and time-to-event endpoints. However, it is excluded because: 1) The trial phase is not explicitly stated as Phase III/IIIb or Phase II/III in the provided metadata, and we cannot infer it from the drug name or context. 2) The report is a pre-planned analysis of prognostic factors, which qualifies as a secondary analysis (report_type: 'secondary'), not the primary definitive result of the drug intervention trial. Therefore, it does not meet the criterion for an original formal-result report of a Phase III/IIIb or Phase II/III randomized trial with primary/key secondary time-to-event efficacy endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Effects of Dapagliflozin on Hospitalizations in Patients With Chronic Kidney Disease : A Post Hoc Analysis of DAPA-CKD. PMID 36469914 · Ann Intern Med · 2023-Jan 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Cobimetinib Alone and Plus Venetoclax With/Without Atezolizumab in Patients With Relapsed/Refractory Multiple Myeloma. PMID 36450626 · Clin Lymphoma Myeloma Leuk · 2023-Jan The study is a phase Ib/II trial with a primary efficacy endpoint of overall response rate (ORR), which is a categorical endpoint. There is no indication of a time-to-event efficacy endpoint (e.g., OS, PFS, DFS, EFS, RFS, TTP) or reporting of Kaplan-Meier curves or hazard ratios in the provided abstract. Therefore, it does not meet the criteria for inclusion in the Kaplan-Meier digitization cohort. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Robot-assisted Partial Nephrectomy with the Newly Developed KangDuo Surgical Robot Versus the da Vinci Si Surgical System: A Double-center Prospective Randomized Controlled Noninferiority Trial. PMID 36446724 · Eur Urol Focus · 2023-Jan 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| Objective response rate of placebo in randomized controlled trials of anticancer medicines. PMID 36444211 · EClinicalMedicine · 2023-Jan The record describes a pooled analysis of placebo response rates in multiple RCTs. It is not an original result report of a single randomized trial with a drug intervention and a primary/key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS). |
H
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Neo-peripheral adaptive immune score predicts neoadjuvant chemotherapy for locally advanced breast cancer. PMID 36409395 · Breast Cancer Res Treat · 2023-Jan The record does not explicitly establish the trial phase as Phase III/IIIb or Phase II/III. The primary efficacy endpoint is pathological complete response (pCR), which is not a time-to-event endpoint. The time-to-event analysis (progression-free interval) is a secondary/exploratory analysis using an external database (TCGA-BRCA), not the primary trial outcome. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Corrigendum to 'Health-related quality of life in patients with advanced well-differentiated pancreatic and extrapancreatic neuroendocrine tumors treated with surufatinib versus placebo: Results from two randomized, double-blind, phase III trials (SANET-p and SANET-ep)' [European Journal of Cancer 169 (2022) 1-9]. PMID 36402625 · Eur J Cancer · 2023-Jan The record is a corrigendum to a study on health-related quality of life, not a time-to-event efficacy endpoint, and is not an original result report of the trial. |
H
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Safety and Efficacy of Upadacitinib for Atopic Dermatitis in Japan: 2-Year Interim Results from the Phase 3 Rising Up Study. PMID 36401761 · Dermatol Ther (Heidelb) · 2023-Jan The study is a phase 3 randomized trial with a drug intervention (upadacitinib) and reports efficacy results. However, it is not an oncology study; it evaluates atopic dermatitis, a chronic inflammatory skin disease. Additionally, the primary efficacy endpoints are clinical response rates (EASI 75/90, vIGA-AD 0/1, WP-NRS), not time-to-event outcomes such as OS, PFS, DFS, or survival analyses. |
H
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| A randomized phase 2 trial of nintedanib and low-dose cytarabine in elderly patients with acute myeloid leukemia ineligible for intensive chemotherapy. PMID 36399194 · Ann Hematol · 2023-Jan 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Treatment with COLchicine in hospitalized patients affected by COVID-19: The COLVID-19 trial. PMID 36396522 · Eur J Intern Med · 2023-Jan 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Thrombocytopenia limits the feasibility of salvage lomustine chemotherapy in recurrent glioblastoma: a secondary analysis of EORTC 26101. PMID 36379185 · Eur J Cancer · 2023-Jan 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Mocravimod, a Selective Sphingosine-1-Phosphate Receptor Modulator, in Allogeneic Hematopoietic Stem Cell Transplantation for Malignancy. PMID 36343893 · Transplant Cell Ther · 2023-Jan The study is a randomized trial in oncology with a drug intervention and an original result report, but it does not meet the definitive Phase III/IIIb or Phase II/III requirement, and the abstract does not provide a primary or key secondary time-to-event efficacy endpoint with KM data or HR suitable for digitization. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Design and Rationale for a Phase II, Randomized, Open-Label, Two-Cohort Multicenter Interventional Study of Osimertinib with or Without Savolitinib in De Novo MET Aberrant, EGFR-Mutant Patients with Advanced Non-Small-Cell Lung Cancer: The FLOWERS Trial. PMID 36333268 · Clin Lung Cancer · 2023-Jan 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Re. Effect of Robot-assisted Radical Cystectomy with Intracorporeal Urinary Diversion vs Open Radical Cystectomy on 90-Day Morbidity and Mortality Among Patients with Bladder Cancer: A Randomized Clinical Trial. PMID 36253307 · Eur Urol · 2023-Jan The study is a randomized trial in oncology (bladder cancer) with a primary efficacy endpoint of 90-day morbidity and mortality, which is not a time-to-event endpoint like OS/PFS. The intervention is surgical (robot-assisted vs open radical cystectomy), not a drug intervention. Therefore, it does not meet the key criteria of having a drug intervention and a time-to-event primary/key secondary efficacy endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Utilization of real-world data in assessing treatment effectiveness for diffuse large B-cell lymphoma. PMID 36251361 · Am J Hematol · 2023-Jan 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Clinical Efficacy of Neoadjuvant Intravesical Mitomycin-C Therapy Immediately Before Transurethral Resection of Bladder Tumor in Patients With Nonmuscle-invasive Bladder Cancer: Preliminary Results of a Prospective, Randomized Phase II Study. PMID 36250938 · J Urol · 2023-Jan 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Less is More? First Impressions From COSMIC-313. PMID 36239611 · Cancer Invest · 2023-Jan The record is a commentary on the first results of a phase 3 randomized trial, not the original primary result report. Furthermore, the abstract does not explicitly mention any time-to-event endpoint (OS, PFS, etc.) or its analysis method (Kaplan-Meier, HR). |
H
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX)-a randomized phase II trial of the AIO pancreatic cancer group. PMID 36209981 · Ann Oncol · 2023-Jan 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Reduced-dose post-transplant cyclophosphamide plus low-dose post-transplant anti-thymocyte globulin as graft-versus-host disease prophylaxis with fludarabine-busulfan-cytarabine conditioning in haploidentical peripheral blood stem cell transplantation: A multicentre, randomized controlled clinical trial. PMID 36200642 · Br J Haematol · 2023-Jan The record is a randomized trial with primary efficacy endpoints, but the required explicit evidence for a Phase III/IIIb or Phase II/III trial is not provided in the title, abstract, or metadata, preventing eligibility confirmation. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |